Correlation of Currently Used Radiobiological Parameters with Local Control and Acute and Late Mucosal Toxicity in Randomised Studies of Altered Fractionation for Locally Advanced Head and Neck Cancer

Clinical Oncology

Volumn 23, Issue 1, 2011, Pages 29-33

  Hartley, A ^a   Sanghera, P ^a   Kazi, W ^a   Mehanna, H ^b   McConkey, C ^c   Glaholm, J ^a   Fowler, J ^d  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

^c UNIVERSITY OF WARWICK   (United Kingdom)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Acute mucositis; Dose escalation; Head and neck cancer; Late mucosal reactions; Radiobiological modelling; Squamous cell carcinoma

Indexed keywords

ADVANCED CANCER; ARTICLE; HEAD AND NECK CANCER; HUMAN; INTENSITY MODULATED RADIATION THERAPY; META ANALYSIS (TOPIC); MUCOSA INFLAMMATION; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RADIATION INJURY; RADIOBIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN ATROPHY; TUMOR GROWTH;

ACUTE DISEASE; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; HEAD AND NECK NEOPLASMS; HUMANS; MODELS, BIOLOGICAL; MUCOSITIS; MUCOUS MEMBRANE; RADIOBIOLOGY; RADIOTHERAPY DOSAGE; RADIOTHERAPY, INTENSITY-MODULATED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 78650417742     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2010.08.007     Document Type: Article

References (19)

1. Kasibhatla M., Kirkpatrick J., Brizel D. How much radiation is the chemotherapy worth in advanced head and neck cancer?. Int J Radiat Oncol Biol Phys 2007, 68:1491-1495.
2. Fowler J. Correction to Kasibhatla et al. (Int J Radiat Oncol Biol Phys 2007;68:1491-1495). How much radiation is the chemotherapy worth in advanced head and neck cancer?. Int J Radiat Oncol Biol Phys 2008, 71:326-329.
3. Lee I., Eisbruch A. Mucositis versus tumor control: the therapeutic index of adding chemotherapy to irradiation of head and neck cancer. Int J Radiat Oncol Biol Phys 2009, 75(4):1060-1063.
4. Hartley A., Sanghera P., Glaholm J., et al. Radiobiological modelling of the therapeutic ratio for the addition of synchronous chemotherapy to radiotherapy in locally advanced squamous cell carcinoma of the head and neck. Clin Oncol 2010, 22:125-130.
5. Bourrhis J., Overgaard J., Audry H., et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 2006, 368(9538):843-854.
6. Bourrhis J., Lapeyre M., Tortochaux J., et al. Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial. J Clin Oncol 2006, 24:2873-2878.
7. Horiot J.C., Le Fur R., N'Guyen T., et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 1992, 25:231-241.
8. Dische S., Saunders M., Barrett A., et al. A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol 1997, 44(2):123-136.
9. Bentzen S., Saunders M., Dische S., et al. Radiotherapy-related early morbidity in head and neck cancer: quantitative clinical radiobiology as deduced from the CHART trial. Radiother Oncol 2001, 60:123-135.
10. Poulsen M.G., Denham J.W., Peters L.J., et al. A randomised trial of accelerated and conventional radiotherapy for stage III and IV squamous carcinoma of the head and neck: a Trans-Tasman Radiation Oncology Group study. Radiother Oncol 2001, 60:113.
11. Overgaard J., Hansen H., Specht L., et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6&7 randomised controlled trial. Lancet 2003, 362:933-940.
12. Fu K., Pajak T., Trotti A., et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000, 48:7-16.
13. Horiot J., Bontemps P., van den Bogaert W., et al. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves locoregional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomised trial. Radiother Oncol 1997, 44:111-121.
14. Fakhry C., Westra W., Li S., et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008, 100:261-269.
15. Caudell J., Meredith R., Spencer S., et al. Margin on gross tumor volume and risk of local recurrence in head and neck cancer. Int J Radiat Oncol Biol Phys 2010, 76:164-168.
16. Lee I. In reply to Dr Hartley. Int J Radiat Oncol Biol Phys 2009, 75:315.
17. Dorr W., Hamilton C., Boyd T., et al. Radiation induced changes in cellularity and proliferation in human oral mucosa. Int J Radiat Oncol Biol Phys 2002, 52:911-917.
18. Fowler J.F., Harari P.M., Leborgne F., et al. Acute radiation reactions in oral and pharyngeal mucosa: tolerable levels in altered fractionation schedules. Radiother Oncol 2003, 69:161-168.
19. Fowler J.F. Is there an optimum overall time for head and neck radiotherapy. A review with new modelling. Clin Oncol 2007, 19:8-22.